Acadia Pharmaceuticals | ACAD - Net Income

Stock Price
24.23
Daily Change
-0.53 -2.14%
Monthly
-7.34%
Yearly
23.62%
Q1 Forecast
24.36

Acadia Pharmaceuticals reported $71.78M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
ALKERMES USD 82.76M 4.34M Sep/2025
Alnylam Pharmaceuticals USD 251.08M 317.36M Sep/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Bristol-Myers Squibb USD 2.2B 891M Sep/2025
Corcept Therapeutics USD 19.67M 15.48M Sep/2025
Cytokinetics USD -306.18M 171.81M Sep/2025
Eisai JPY 10.16B 4.32B Sep/2025
Eli Lilly USD 5.58B 78M Sep/2025
Incyte USD 424.17M 19.17M Sep/2025
J&J USD 5.12B 36M Dec/2025
Moderna USD -200M 625M Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Prothena USD -36.54M 89.23M Sep/2025
PTC Therapeutics USD 15.9M 80.75M Sep/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
Ultragenyx Pharmaceutical USD -180.41M 65.46M Sep/2025
Vertex Pharmaceuticals USD 1.08B 50M Sep/2025